MarketMoodz
Roche CEO laments Swiss franc strength as U.S. investment push continues
Roche posted Q1 2026 sales of 14.7 billion Swiss francs, down 5% year over year, hit by a stronger franc on translation. The company also signaled a continued push to invest in the United States, underscoring USD exposure as it leans on US activity for growth.
Key Takeaways
- Q1 2026 sales were 14.7 billion CHF, down 5% YoY, with constant-currency growth of 6%.
- USD-denominated sales rose 9% on a reported basis despite CHF strength.
- Swiss franc appreciated 12% against the USD in 2025 and has fallen about 1% so far in 2026, creating translation headwinds.
- Roche spends the majority of its money in the United States and carries most of its debt in USD, amplifying currency exposure.
- Roche recently acquired a U.S.-based company and plans to continue investing there, strengthening US footprint.
People Involved
- Thomas SchineckerRoche CEO
Entities Involved
- RochePharmaceutical company
- Novo NordiskBiopharma competitor
- Eli LillyPharmaceutical company
MarketMoodz Analysis
FX dynamics dominate Roche’s reported earnings. With CHF translation weighing on CHF-denominated revenue even as USD-denominated sales grow, the earnings mix is juggling currency moves with underlying volume and product mix.
The US investment tilt matters for investors: higher USD cash flow helps top-line growth in dollar terms, but USD-denominated costs and hedging can pressure margins if currency swings widen. Roche’s debt profile being USD-centric adds another layer of sensitivity to FX moves and macro policy bets.
A note on the CT-388 weight-loss claim: Roche has discussed a weight-loss program, but independent verification is needed and the drug’s market prospects remain uncertain. Watch how Roche’s forward-looking pipeline, FX hedging strategy, and competitive positioning with Novo Nordisk and Eli Lilly evolve in the coming quarters.
Source: Original Article